{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,8,19]],"date-time":"2023-08-19T18:27:43Z","timestamp":1692469663909},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2008,5,29]],"date-time":"2008-05-29T00:00:00Z","timestamp":1212019200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"published-print":{"date-parts":[[2008,12]]},"DOI":"10.1186\/1471-230x-8-20","type":"journal-article","created":{"date-parts":[[2008,5,30]],"date-time":"2008-05-30T06:13:31Z","timestamp":1212128011000},"source":"Crossref","is-referenced-by-count":5,"title":["Short-term triple therapy with azithromycin for Helicobacter pylori eradication: Low cost, high compliance, but low efficacy"],"prefix":"10.1186","volume":"8","author":[{"given":"Fernando M","family":"Silva","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaime N","family":"Eisig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana Cristina S","family":"Teixeira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ricardo C","family":"Barbuti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tom\u00e1s","family":"Navarro-Rodriguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rejane","family":"Mattar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,5,29]]},"reference":[{"key":"253_CR1","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1001\/jama.1994.03520010077036","volume":"272","author":"NIH Consensus Development Panel on H. pylori in peptic ulcer disease","year":"1994","unstructured":"NIH Consensus Development Panel on H. pylori in peptic ulcer disease: Helicobacter pylori in peptic ulcer disease. JAMA. 1994, 272: 65-69. 10.1001\/jama.272.1.65.","journal-title":"JAMA"},{"key":"253_CR2","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1046\/j.1365-2036.2002.01169.x","volume":"16","author":"P Malfertheiner","year":"2002","unstructured":"Malfertheiner P, Megraud F, O'Morain C, Hungin APS, Jones R, Axon A, Grahan DY, Tytgat GI, European Helicobacter pylori Study Group (EHPSG): Current concepts in the management of Helicobacter pylori infection \u2013 The Maastricht 2 \u2013 2000 Consensus report. Aliment Pharmacol Ther. 2002, 16: 167-80. 10.1046\/j.1365-2036.2002.01169.x.","journal-title":"Aliment Pharmacol Ther"},{"key":"253_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1440-1746.1998.tb00537.x","volume":"13","author":"SK Lam","year":"1998","unstructured":"Lam SK, Talley NJ: Report of the 1997 ASIA Pacific Consensus Conference on the management of Helicobacter pylori infection. J Gastroenterol Hepatol. 1998, 13: 1-12. 10.1111\/j.1440-1746.1998.tb00537.x.","journal-title":"J Gastroenterol Hepatol"},{"key":"253_CR4","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1155\/2004\/326767","volume":"18","author":"RH Hunt","year":"2004","unstructured":"Hunt RH, Fallone CA, Veldhuyzan van Zanten S, Sherman P, Smaill F, Flook N, Thomson A, CHSG 2004 participants: Canadian Helicobacter Study Group Consensus Conference: Update on the management of Helicobacter pylori \u2013 an evidence-based evaluation of six topics relevant to clinical out comes in patients evaluated for H. pylori infection. Can J Gastroenterol. 2004, 18: 547-54.","journal-title":"Can J Gastroenterol"},{"key":"253_CR5","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1590\/S0004-28032005000200012","volume":"42","author":"LVG Coelho","year":"2005","unstructured":"Coelho LVG, Zaterka S, representatives of the Brazilian Federation of Gastroenterology and Brazilian Nucleus for the study of Helicobacter pylori: Second Brazilian Consensus Conference on Helicobacter pylori Infection. Arq Gastroenterol. 2005, 42: 128-32.","journal-title":"Arq Gastroenterol"},{"key":"253_CR6","doi-asserted-by":"publisher","first-page":"2688","DOI":"10.1111\/j.1572-0241.2000.03174.x","volume":"95","author":"LGV Coelho","year":"2000","unstructured":"Coelho LGV, Leon-Barua R, Quigley EMM: Latin-American Consensus Conference on Helicobacter pylori infection. Am J Gastroenterol. 2000, 95: 2688-91.","journal-title":"Am J Gastroenterol"},{"key":"253_CR7","doi-asserted-by":"publisher","first-page":"27","DOI":"10.3109\/00365529609094747","volume":"220","author":"P Unge","year":"1996","unstructured":"Unge P, Berstad A: Pooled analysis of anti-Helicobacter pylori treatment regimens. Scand J Gastroentrol Suppl. 1996, 220: 27-40. 10.3109\/00365529609094747.","journal-title":"Scand J Gastroentrol Suppl"},{"key":"253_CR8","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1046\/j.1365-2036.1998.00405.x","volume":"12","author":"GA Pipkin","year":"1998","unstructured":"Pipkin GA, Williamson R, Wood JR: Review article: one-week clarithromycin triple therapy regimens for eradication of Helicobacter pylori. Aliment Pharmacol Ther. 1998, 12: 823-37. 10.1046\/j.1365-2036.1998.00405.x.","journal-title":"Aliment Pharmacol Ther"},{"key":"253_CR9","first-page":"1716","volume":"87","author":"N Chiba","year":"1992","unstructured":"Chiba N, Rao BV, Rademaker JW, Hunt RH: Meta-analysis of the efficacy of antibiotic therapy in eradicating Helicobacter pylori. Am J Gastroenterol. 1992, 87: 1716-27.","journal-title":"Am J Gastroenterol"},{"key":"253_CR10","doi-asserted-by":"publisher","first-page":"747","DOI":"10.3748\/wjg.v10.i5.747","volume":"10","author":"CY Guo","year":"2004","unstructured":"Guo CY, Wu YB, Liu HL, Wu JY, Zhong MB: Clinical evaluation of four one-week triple therapy regimens in eradicating Helicobacter pylori infection. World J Gastroenterol. 2004, 10: 747-9.","journal-title":"World J Gastroenterol"},{"key":"253_CR11","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1046\/j.1365-2036.2000.00846.x","volume":"14","author":"G Cammarota","year":"2000","unstructured":"Cammarota G, Cianci R, Cannizzaro O, Cuoco L, Pirozzi G, Gasbarrini A, Armuzzi A, Zocco MA, Santarelli A, Arancio F, Gasbarrini G: Efficacy of two one-week rabeprazole\/levoflaxacin-based triple therapies for Helicobacter pylori infection. Aliment Pharmacol Ther. 2000, 14: 1339-43. 10.1046\/j.1365-2036.2000.00846.x.","journal-title":"Aliment Pharmacol Ther"},{"key":"253_CR12","first-page":"1545","volume":"85","author":"I Glupczynski","year":"1990","unstructured":"Glupczynski I, Burette A: Drug therapy for Helicobacter pylori infection: Problems and pitfalls. Am J Gastroenterol. 1990, 85: 1545-51.","journal-title":"Am J Gastroenterol"},{"key":"253_CR13","first-page":"505","volume":"88","author":"AF Cutler","year":"1993","unstructured":"Cutler AF, Schubert TT: Patient's factors affecting Helicobacter pylori eradication with triple therapy. Am J Gastroenterol. 1993, 88: 505-9.","journal-title":"Am J Gastroenterol"},{"key":"253_CR14","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1046\/j.1365-2036.1998.00405.x","volume":"12","author":"GA Pipkin","year":"1998","unstructured":"Pipkin GA, Williamson R, Wood JR: Review article: one-week clarithromycin triple therapy regimens for eradication of Helicobacter pylori. Aliment Pharmacol Ther. 1998, 12: 823-837. 10.1046\/j.1365-2036.1998.00405.x.","journal-title":"Aliment Pharmacol Ther"},{"key":"253_CR15","doi-asserted-by":"crossref","unstructured":"Qasin A, O'Morain CA: Review article: Treatment of Helicobacter pylori infection and factors influencing eradication. Aliment Pharmacol Ther. 2002, 24-30. 10.1046\/j.1365-2036.2002.0160s1024.x. suppl 1","DOI":"10.1046\/j.1365-2036.2002.0160s1024.x"},{"key":"253_CR16","doi-asserted-by":"publisher","first-page":"2393","DOI":"10.1111\/j.1572-0241.2005.00286.x","volume":"100","author":"N Vakil","year":"2005","unstructured":"Vakil N: Helicobacter pylori: factors affecting eradication e recurrence. Am J Gastroenterol. 2005, 100: 2393-4. 10.1111\/j.1572-0241.2005.00286.x.","journal-title":"Am J Gastroenterol"},{"key":"253_CR17","first-page":"322","volume":"88","author":"DMM Queiroz","year":"1993","unstructured":"Queiroz DMM, Coimbra RS, Mendes EN, Rocha GA, Alves VM, Oliveira CA, Lima J\u00fanior GF: Metronidazole resistant Helicobacter pylori in a developing country. Am J Gastroenterol. 1993, 88: 322-3.","journal-title":"Am J Gastroenterol"},{"key":"253_CR18","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1046\/j.1523-5378.2000.00011.x","volume":"5","author":"S Mendon\u00e7a","year":"2000","unstructured":"Mendon\u00e7a S, Ecclissato C, Sartori MS, Godoy AP, Guerzone RA, Degger M, Pedrazzoli J: Prevalence of Helicobacter pylori resistance to metronidazole, clarithromycin, amoxicillin, tetracycline, and furazolidone in Brazil. Helicobacter. 2000, 5: 79-83. 10.1046\/j.1523-5378.2000.00011.x.","journal-title":"Helicobacter"},{"key":"253_CR19","volume-title":"As condi\u00e7\u00f5es de sa\u00fade no Brasil \u2013 Retrospecto 1979 a 1995","author":"JB Risi J\u00fanior","year":"2000","unstructured":"Risi J\u00fanior JB, Nogueira RP: As condi\u00e7\u00f5es de sa\u00fade no Brasil \u2013 Retrospecto 1979 a 1995. 2000, Rio de Janeiro: Editora Fiocruz, [ http:\/\/www.fiocruz.br\/editora\/media\/04-CSPB02.pdf ]"},{"key":"253_CR20","first-page":"30","volume":"n","author":"WJ Quadros","year":"2001","unstructured":"Quadros WJ, Antunes DJN: Classes sociais e distribui\u00e7\u00e3o de renda no Brasil dos anos noventa. Cadernos do CESIT. 2001, n: 30-[ http:\/\/www.eco.unicamp.br\/Downloads\/publicacoes\/cesit\/cadernodoCESIT30.pdf ]","journal-title":"Classes sociais e distribui\u00e7\u00e3o de renda no Brasil dos anos noventa. Cadernos do CESIT"},{"key":"253_CR21","volume-title":"Nota t\u00e9cnica \u2013 DIEESE","author":"Sal\u00e1rio M\u00ednimo e distribui\u00e7\u00e3o de renda","year":"2005","unstructured":"Sal\u00e1rio M\u00ednimo e distribui\u00e7\u00e3o de renda: Nota t\u00e9cnica \u2013 DIEESE. 2005, n.6, [ http:\/\/www.dieese.org.br\/notatecnica\/notatecSMDR.pdf ]"},{"key":"253_CR22","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1046\/j.1365-2036.1999.00530.x","volume":"13","author":"J Huang","year":"1999","unstructured":"Huang J, Hunt RH: The importance of clarithromycin dose in the management of Helicobacter pylori infection: a meta-analysis of triple therapies with a proton pump inhibitor, clarithromycin and amoxicillin or metronidazole. Aliment Pharmacol Ther. 1999, 13: 719-29. 10.1046\/j.1365-2036.1999.00530.x.","journal-title":"Aliment Pharmacol Ther"},{"key":"253_CR23","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1046\/j.1365-2036.1996.95267000.x","volume":"10","author":"AF Goddard","year":"1996","unstructured":"Goddard AF, Spiller RC: Helicobacter pylori eradication in clinical practice: one-week low-dose triple therapy is preferable to classical bismuth based triple therapy. Aliment Pharmacol Ther. 1996, 10: 1009-13. 10.1046\/j.1365-2036.1996.95267000.x.","journal-title":"Aliment Pharmacol Ther"},{"key":"253_CR24","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1046\/j.1365-2036.2002.01173.x","volume":"16","author":"U Peitz","year":"2002","unstructured":"Peitz U, Sulliga M, Wolle K, Leodolter A, Von Armim U, Kahl S, Stolte M, B\u00f6rsch G, Labens J, Malfertheiner P: High rate of post-therapeutic resistance after failure of macrolide-nitroimidazole triple therapy to cure Helicobacter pylori infection: impact of two second-line therapies in a randomized study. Aliment Pharmacol Ther. 2002, 16: 315-24. 10.1046\/j.1365-2036.2002.01173.x.","journal-title":"Aliment Pharmacol Ther"},{"key":"253_CR25","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1590\/S0004-28032004000100014","volume":"41","author":"LGV Coelho","year":"2004","unstructured":"Coelho LGV, Mattos AA, Francisconi CFM, Castro LP, Andre SB: Efficacy of the dosing regimen of pantoprazole 40 mg, amoxicillin 1000 mg and clarithromycin 500 mg, twice daily for 7 days, in the eradication of the Helicobacter pylori in patients with peptic ulcer. Arq Gastroenterol. 2004, 41: 71-6.","journal-title":"Arq Gastroenterol"},{"key":"253_CR26","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1046\/j.1523-5378.2002.00056.x","volume":"7","author":"T Ecclissato","year":"2002","unstructured":"Ecclissato T, Marchioretto MAM, Mendon\u00e7a S, Godoy AP, Guersoni RA, Deguer M, Piovesan H, Ferraz JG, Pedrazzoli J: Increased primary resistance to recommended antibiotics negatively affects Helicobacter pylori eradication. Helicobacter. 2002, 7: 53-9. 10.1046\/j.1523-5378.2002.00056.x.","journal-title":"Helicobacter"},{"key":"253_CR27","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.1128\/AAC.46.6.2021-2023.2002","volume":"46","author":"PP Magalhaes","year":"2002","unstructured":"Magalhaes PP, Queiroz DMM, Barbosa DVC, Rocha GA, Mendes EN, Santos A, Valle Corr\u00eaa PR, Camargos Rocha AM, Martins Teixeira L, Affonso de Oliveira C: Helicobacter pylori primary resistance to Metronidazole and Clarithromycin in Brazil. Antimicrob Agents Chemother. 2002, 46: 2021-3. 10.1128\/AAC.46.6.2021-2023.2002.","journal-title":"Antimicrob Agents Chemother"},{"key":"253_CR28","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/1471-230X-3-20","volume":"3","author":"APO Godoy","year":"2003","unstructured":"Godoy APO, Ribeiro ML, Benvengo YHB, Vitiello L, Miranda MC, Mendon\u00e7a S, Pedrazzoli J: Analysis of antimicrobial susceptibility and virulence factors in Helicobacter pylori clinical isolates. BMC Gastroenterol. 2003, 3: 20-10.1186\/1471-230X-3-20.","journal-title":"BMC Gastroenterol"},{"key":"253_CR29","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.1128\/AAC.31.12.1939","volume":"31","author":"J Retsema","year":"1987","unstructured":"Retsema J, Girard A, Schelkly W, Manousos M, Anderson M, Bright G, Borovoy R, Brennan L, Mason R: Spectrum and mode of action of azithromycin (CP-62,993), a new 15-membered-ring macrolide with improved potency against gram-negative organisms. Antimicrob Agents Chemother. 1987, 31: 1939-47.","journal-title":"Antimicrob Agents Chemother"},{"key":"253_CR30","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1093\/jac\/42.1.75","volume":"42","author":"C Blandizzi","year":"1998","unstructured":"Blandizzi C, Malizia T, Gherardi G, Costa F, Marchi S, Marveggio C, Natale G, Senesi S, Bellini M, Maltinti G, Campa M, Tacca MD: Gastric mucosal distribution and clinical efficacy of azithromycin in patients with Helicobacter pylori related gastritis. J Antimicrob Chemother. 1998, 42: 75-82. 10.1093\/jac\/42.1.75.","journal-title":"J Antimicrob Chemother"},{"key":"253_CR31","first-page":"264","volume":"91","author":"F Di Mario","year":"1996","unstructured":"Di Mario F, Dal B\u00f3 N, Grassi AS, Cannizzaro O, Armuzzi A, Gasbarrini A, Addolorato G, Gasbarrini GB: Azithromycin for the cure of Helicobacter pylori infection. Am J Gastroenterol. 1996, 91: 264-7.","journal-title":"Am J Gastroenterol"},{"key":"253_CR32","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1097\/00042737-199701000-00012","volume":"9","author":"M Caselli","year":"1997","unstructured":"Caselli M, Trevisani L, Tursi A, Sartori S, Ruina M, Luzzi I, Gaudenzi P, Alvisi V, Gasbarrini G: Short-term low-dose triple therapy with azithromycin, metronidazole and lansoprazole appears highly effective for the eradication of Helicobacter pylori. Eur J Gastroenterol Hepatol. 1997, 9: 45-8.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"253_CR33","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1046\/j.1365-2036.1998.00422.x","volume":"12","author":"WD Chey","year":"1998","unstructured":"Chey WD, Fisher L, Barnett J, Delvalle J, Elta GH, Hasler WL, Nostrant T, Palaniappan J, Scheiman J: Low-versus high-dose azithromycin triple therapy for Helicobacter pylori infection. Aliment Pharmacol Ther. 1998, 12: 1263-7. 10.1046\/j.1365-2036.1998.00422.x.","journal-title":"Aliment Pharmacol Ther"},{"key":"253_CR34","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1046\/j.1365-2036.2000.00879.x","volume":"14","author":"C Calabrese","year":"2000","unstructured":"Calabrese C, Di Febo G, Areni A, Scilapi C, Biasco G, Miglioni M: Pantoprazole, azithromycin and tinidazole: short duration triple therapy for eradication of Helicobacter pylori infection. Aliment Pharmacol Ther. 2000, 14: 1613-17. 10.1046\/j.1365-2036.2000.00879.x.","journal-title":"Aliment Pharmacol Ther"},{"key":"253_CR35","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1093\/ajhp\/58.19.1819","volume":"58","author":"C Chahine","year":"2001","unstructured":"Chahine C, Moukhachen O, Chedid M, Araj GF, Sharara AI: Ultrashort regimen of lansoprazole-amoxicillin-azithromycin for eradicating Helicobacter pylori. Am J Health Syst Pharm. 2001, 58: 1819-23.","journal-title":"Am J Health Syst Pharm"},{"key":"253_CR36","doi-asserted-by":"publisher","first-page":"2536","DOI":"10.1111\/j.1572-0241.2002.06036.x","volume":"97","author":"B Sullivan","year":"2002","unstructured":"Sullivan B, Coyle W, Nemec R, Dunteman T: Comparison of azithromycin and clarithromycin in triple therapy regimens for the eradication of Helicobacter pylori. Am J Gastroenterol. 2002, 97: 2536-9. 10.1111\/j.1572-0241.2002.06036.x.","journal-title":"Am J Gastroenterol"},{"key":"253_CR37","doi-asserted-by":"publisher","first-page":"G0382","DOI":"10.1016\/S0016-5085(98)80379-X","volume":"114","author":"LG Coelho","year":"1998","unstructured":"Coelho LG, Vieira WL, Passos MC, Chausson Y, Castro FJ, Franco JM, Yazaki FR, Costa AC, Andrade JM, Castro LP: Azithromycin, furazolidone and omeprazole: a promising low-dose, low cost, short-term, anti-H. pylori triple therapy. Gastroenterology. 1998, 114: G0382-10.1016\/S0016-5085(98)80379-X.","journal-title":"Gastroenterology"},{"key":"253_CR38","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1590\/S0041-87812002000100002","volume":"57","author":"FM Silva","year":"2002","unstructured":"Silva FM, Eisig JN, Chether EZ, da Silva JJ, Laudanna AA: Low efficacy of an ultra-short term, once-daily dose triple therapy with omeprazole, azithromycin and secnidazole for Helicobacter pylori eradication in peptic ulcer. Rev Hosp Clin Fac Med Sao Paulo. 2002, 57: 9-14.","journal-title":"Rev Hosp Clin Fac Med Sao Paulo"},{"key":"253_CR39","unstructured":"Minist\u00e9rio da Sa\u00fade. Farm\u00e1cia Popular do Brasil. [ http:\/\/portal.saude.gov.br\/portal\/arquivos\/pdf\/medicamentosfarmaciapopular.pdf ]"},{"issue":"2","key":"253_CR40","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1590\/S1413-81232007000200011","volume":"12","author":"UC Pessoto","year":"2007","unstructured":"Pessoto UC, Helmann LS, Boaretto RC, Castro IEN, Kayano J, Ibanhes LC, Junqueira V, Rocha JL, Barboza R, Cortizo CT, Martins LC, Luiz OC: Health care services utilizations and access inequalities in the Sao Paulo Metropolitan region. Cienc Saude Coletiva. 2007, 12 (2): 351-62. [ http:\/\/www.scielo.br\/pdf\/csc\/v12n2\/a11v12n2.pdf ]","journal-title":"Cienc Saude Coletiva"},{"key":"253_CR41","unstructured":"Minist\u00e9rio da Sa\u00fade \u2013 Brasil. Programa Nacional de Controle da Tuberculose. [ http:\/\/portal.saude.gov.br\/portal\/saude\/visualizar_texto.cfm?idtxt=21446 ]"},{"key":"253_CR42","unstructured":"Minist\u00e9rio da Sa\u00fade \u2013 Brasil. Programa Nacional de DST e AIDS. [ http:\/\/portal.saude.gov.br\/portal\/saude\/visualizar_texto.cfm?idtxt=21446 ]"},{"key":"253_CR43","unstructured":"Minist\u00e9rio da Sa\u00fade \u2013 Brasil. Hiperdia \u2013 Sistema de cadastramento e acompanhamento de diab\u00e9ticos e hipertensos. [ http:\/\/hiperdia.datasus.gov.br\/ ]"},{"key":"253_CR44","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1097\/00042737-200501000-00018","volume":"17","author":"PE Arkkila","year":"2005","unstructured":"Arkkila PE, Seppala K, Kosunen TU, Sipponen P, Makinen J, Rautelin H, F\u00e4rkkil\u00e4 M: Helicobacter pylori eradication as the sole treatment for gastric and duodenal ulcers. Eur J Gastroenterol Hepatol. 2005, 17: 93-101. 10.1097\/00042737-200501000-00018.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"253_CR45","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1111\/j.1572-0241.2004.40014.x","volume":"99","author":"AC Ford","year":"2004","unstructured":"Ford AC, Delaney BC, Forman D, Moayyedi P: Eradication therapy in Helicobacter pylori positive peptic ulcer disease: Systematic review and economic analysis. Am J Gastroenterol. 2004, 99: 1833-55. 10.1111\/j.1572-0241.2004.40014.x.","journal-title":"Am J Gastroenterol"},{"key":"253_CR46","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1111\/j.1523-5378.2007.00474.x","volume":"12","author":"S Zaterka","year":"2007","unstructured":"Zaterka S, Eisig JN, Chinzon D, Rothstein W: Factors related to Helicobacter pylori prevalence in adult population in Brazil. Helicobacter. 2007, 12: 82-8. 10.1111\/j.1523-5378.2007.00474.x.","journal-title":"Helicobacter"},{"key":"253_CR47","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/S0035-9203(03)90063-0","volume":"97","author":"RP Almeida Cunha","year":"2003","unstructured":"Almeida Cunha RP, Alves FP, Rocha AM, Rocha GA, Camargo LM, Nogueira PO, Camargo EP, Queiroz DM: Prevalence and risk factors associated with Helicobacter pylori infection in native populations from Brazilian Western Amazon. Trans R Soc Trop Med Hyg. 2003, 97: 382-6. 10.1016\/S0035-9203(03)90063-0.","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"253_CR48","first-page":"339","volume":"7","author":"AC Lira","year":"2003","unstructured":"Lira AC, Santana G, Santana N, Silvany-Neto A, Magalh\u00e3es E, Pereira EM, Mascarenhas R, Lyra MC, Veiga A, Ferreira K, Zaterka S, Lyra LG: Seroprevalence and risk factors associated with Helicobacter pylori infection in blood donors in Salvador, Northeast-Brazil. Braz J Infect Dis. 2003, 7: 339-45.","journal-title":"Braz J Infect Dis"},{"key":"253_CR49","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1097\/00042737-200402000-00013","volume":"16","author":"MN Rodrigues","year":"2004","unstructured":"Rodrigues MN, Queiroz DMM, Bezerra Filho JG, Pontes LK, Rodrigues LT, Braga LL: Prevalence of Helicobacter pylori infection in children from an urban community in north-east Brazil and risk factors for infection. Eur J Gastroenterol Hepatol. 2004, 16: 201-5. 10.1097\/00042737-200402000-00013.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"253_CR50","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1046\/j.1365-2036.2000.00844.x","volume":"14","author":"JP Gisbert","year":"2000","unstructured":"Gisbert JP, Gonzales L, Calvet X, Garcia N, Lopes T, Roque M, Gabriel R, Pajares JM: Proton pump inhibitor, clarithromycin and either amoxicillin or nitroimidazole: a metanalysis of eradication of Helicobacter pylori. Aliment Pharmacol Ther. 2000, 14: 1319-28. 10.1046\/j.1365-2036.2000.00844.x.","journal-title":"Aliment Pharmacol Ther"},{"key":"253_CR51","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1590\/S0041-87812001000100003","volume":"56","author":"FM Silva","year":"2001","unstructured":"Silva FM, Zaterka S, Eisig JM, Chehter EZ, Chinzon D, Laudanna AA: Factors affecting Helicobacter pylori eradication using a seven-day triple therapy with a proton pump inhibitor, tinidazole and clarithromycin in Brazilian patients with peptic ulcer. Rev Hosp Clin Fac Med S Paulo. 2001, 56: 11-6.","journal-title":"Rev Hosp Clin Fac Med S Paulo"},{"key":"253_CR52","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1590\/S0004-28032003000100012","volume":"40","author":"JN Eisig","year":"2003","unstructured":"Eisig JN, Andre SB, Silva FM, Hashimoto C, Moraes-Filho JPP, Laudanna AA: The impact of Helicobacter pylori resistance on the efficacy of a short course pantoprazole based triple therapy. Arq Gastroenterol. 2003, 40: 55-60. 10.1590\/S0004-28032003000100012.","journal-title":"Arq Gastroenterol"},{"key":"253_CR53","unstructured":"Pylori Pac*. Medley, Braz. Medley S.A. Ind\u00fastria Farmac\u00eautica. [ http:\/\/www.medley.com.br\/src\/Area.asp?areaid=%7BCCD7A143-D80E-41B2-A191-81F0101C3DEB%7D ]"},{"key":"253_CR54","unstructured":"Omepramix*. Ache, Braz. Ach\u00e9 Laborat\u00f3rios Farmac\u00eauticos SA. [ http:\/\/www.ache.com.br\/scripts\/produtos\/produto_bula.asp?idProduto=63&stProduto=Omepramix ]"},{"key":"253_CR55","first-page":"130","volume":"31","author":"PA Lotufo","year":"1994","unstructured":"Lotufo PA, Bense\u00f1or IJ, Lolio CA: [Trends of peptic ulcer mortality in S\u00e3o Paulo State (Brazil) 1970\u20131989]. Arq Gastroenterol. 1994, 31: 130-134. Article in Portuguese","journal-title":"Arq Gastroenterol"},{"issue":"2","key":"253_CR56","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/PL00011722","volume":"4","author":"LG Louren\u00e7o","year":"2001","unstructured":"Louren\u00e7o LG, Hamada GS: Gastric cancer in Brazil. Gastric cancer. 2001, 4 (2): 103-105. 10.1007\/PL00011722.","journal-title":"Gastric cancer"},{"key":"253_CR57","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/jac\/25.suppl_A.15","volume":"25 Suppl A","author":"MD Kitzis","year":"1990","unstructured":"Kitzis MD, Goldstein FW, Mi\u00e9gi M, Acar JF: In vitro activity of azithromycin against various gran-negative bacilli and anaerobic bacteria. J Antimicrob Chemother. 1990, 25 Suppl A: 15-18.","journal-title":"J Antimicrob Chemother"},{"key":"253_CR58","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1345\/aph.17299","volume":"32","author":"RP Rapp","year":"1998","unstructured":"Rapp RP: Pharmacokinetics and pharmacodynamics of intravenous and oral azithromycin: enhanced tissue activity and minimal drugs interactions. Ann Pharmacother. 1998, 32: 785-93. 10.1345\/aph.17299.","journal-title":"Ann Pharmacother"},{"key":"253_CR59","first-page":"258","volume":"91","author":"G Bertoni","year":"1996","unstructured":"Bertoni G, Sassatelli R, Nigrisoli E, Tansini P, Bianchi G, Della Casa G, Bagni A, Bedogni G: Triple therapy with azithromycin, omeprazole, and amoxicillin is highly effective in the eradication of Helicobacter pylori: a controlled trial versus omeprazole plus amoxicillin. Am J Gastroenterol. 1996, 91: 258-63.","journal-title":"Am J Gastroenterol"},{"key":"253_CR60","first-page":"209","volume":"52","author":"A Vcev","year":"1998","unstructured":"Vcev A, Vceva A, Takac B, Dmitrovi\u00e6 B, Stimac D, Stimac T, Kovac D, Pezerovi\u00e6 D, Blazanovi\u00e6 A, Ivandi\u00e6 A, Karner I: Omeprazole, azithromycin and amoxicillin or amoxicillin plus clavulanic acid in eradication of Helicobacter pylori in duodenal ulcer disease. Acta Med Croatica. 1998, 52: 209-14.","journal-title":"Acta Med Croatica"},{"issue":"1 Suppl 2","key":"253_CR61","first-page":"107","volume":"57","author":"M Gribajcevi\u00e6","year":"2003","unstructured":"Gribajcevi\u00e6 M, Vanis N, Mesihovi\u00e6 R: Clinical effectiveness of omeprazole, azithromycin and amoxicillin in ulcer healing and eradication of Helicobacter pylori infection. Med Arh. 2003, 57 (1 Suppl 2): 107-10.","journal-title":"Med Arh"},{"key":"253_CR62","first-page":"361","volume":"37","author":"R Krichhoff","year":"1999","unstructured":"Krichhoff R, Laufen H, Schacke G, Kirchhoff G, Gallo E: Determination of Azithromycin in gastric biopsy samples. Int J Clin Pharmacol Ther. 1999, 37: 361-364.","journal-title":"Int J Clin Pharmacol Ther"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-230X-8-20\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-230X-8-20.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-230X-8-20","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-230X-8-20.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T15:15:16Z","timestamp":1684422916000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgastroenterol.biomedcentral.com\/articles\/10.1186\/1471-230X-8-20"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,5,29]]},"references-count":62,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2008,12]]}},"alternative-id":["253"],"URL":"https:\/\/doi.org\/10.1186\/1471-230x-8-20","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,5,29]]},"article-number":"20"}}